Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

VYJUVEK APPROVED FOR THE TREATMENT OF DEB FROM BIRTH WITH FLEXIBLE ADMINISTRATION OPTIONS INCLUDING HOME DOSING AND THE OPTION FOR ADMINISTRATION BY THE PATIENT OR THEIR FAMILY

KRYSTAL BIOTECH ANNOUNCES APPROVAL OF VYJUVEK BY JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

KB304 DESIGNED TO DELIVER COLLAGEN AND ELASTIN TO RESTORE SKIN NATURALLY CONFERENCE CALL TO DISCUSS RESULTS SCHEDULED FOR THURSDAY, JULY 24, 2025 AT 4:30PM ET PITTSBURGH, JULY 24, 2025 (GLOBE NEWSWIRE) -- JEUNE AESTHETICS, INC. (JEUNE), A WHOLLY OWNED SUBSIDIARY OF KRYSTAL BIOTECH, INC. (KRYSTAL) (NASDAQ: KRYS) LEVERAGING KRYSTAL'S CLINICALLY VALIDATED GENE-DELIVERY PLATFORM TO FUNDAMENTALLY REVERSE THE BIOLOGY OF AGING SKIN, ANNOUNCED TODAY POSITIVE SAFETY AND EFFICACY RESULTS, INCLUDING SIGNIFICANT IMPROVEMENTS IN KEY SKIN AESTHETIC ATTRIBUTES SUCH AS WRINKLES AND ELASTICITY, IN PEARL-2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1 STUDY EVALUATING KB304, FOR THE TREATMENT OF WRINKLES OF THE DCOLLET. MEANINGFUL AESTHETIC IMPROVEMENTS WERE REPORTED FOLLOWING KB304 TREATMENT WITH CLEAR AND STATISTICALLY SIGNIFICANT ADVANTAGES OVER PLACEBO AS EVALUATED BY BOTH THE INVESTIGATOR AND SUBJECTS USING THE GLOBAL AESTHETIC IMPROVEMENT SCALE (GAIS).

JEUNE ANNOUNCES POSITIVE RESULTS AND SIGNIFICANT AESTHETIC IMPROVEMENTS FROM PHASE 1 STUDY OF KB304 FOR MODERATE TO SEVERE WRINKLES OF THE DCOLLET

EYE DROP ADMINISTRATION OF KB801 DESIGNED TO ENABLE SUSTAINED EXPRESSION OF NGF IN THE FRONT OF THE EYE INVESTOR CALL AND WEBCAST TO BE HELD JULY 9 AT 8:30 AM ET TO DISCUSS PROGRAM AND TRIAL DESIGN PITTSBURGH, JULY 09, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 1/2 CLINICAL TRIAL (EMERALD-1), A 2:1 RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PLACEBO-CONTROLLED STUDY EVALUATING KB801 FOR THE TREATMENT OF NEUROTROPHIC KERATITIS (NK). OUR OPHTHALMOLOGY PIPELINE IS WELL UNDER WAY WITH THE DOSING OF OUR FIRST PATIENT IN EMERALD-1, ALONG WITH INITIATION OF OUR PHASE 3 IOLITE STUDY IN DEB, SAID SUMA KRISHNAN, PRESIDENT, RESEARCH & DEVELOPMENT, KRYSTAL BIOTECH, INC. UNTIL NOW, RAPID PROTEIN CLEARANCE RATES AND HIGH CELL TURNOVER IN THE FRONT OF THE EYE HAVE SEVERELY LIMITED THE THERAPEUTIC POTENTIAL OF BIOLOGICS AND GENE THERAPIES FOR THE TREATMENT OF CORNEAL EPITHELIAL DEFECTS AND OTHER FRONT OF THE EYE DISEASES.

KRYSTAL BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2 TRIAL OF KB801 FOR THE TREATMENT OF NEUROTROPHIC KERATITIS

INTRA-PATIENT, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY WITH CROSSOVER DESIGN REPEAT ADMINISTRATION UNDER COMPASSIONATE USE WAS PREVIOUSLY SHOWN TO BE WELL TOLERATED AND ASSOCIATED WITH FULL CORNEAL HEALING BY 3 MONTHS AS WELL AS SIGNIFICANT VISUAL ACUITY IMPROVEMENT FROM HAND MOTION TO 20/25 AT 8 MONTHS PITTSBURGH, JUNE 24, 2025 (GLOBE NEWSWIRE) --  KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT THE FIRST PATIENT HAS BEEN DOSED IN ITS PHASE 3 CLINICAL TRIAL (IOLITE), AN INTRA-PATIENT, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED STUDY WITH CROSSOVER DESIGN EVALUATING KB803 FOR THE TREATMENT AND PREVENTION OF CORNEAL ABRASIONS IN DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) PATIENTS. KB803 IS DESIGNED TO DELIVER TWO COPIES OF THE COL7A1 TRANSGENE TO THE CORNEAL EPITHELIUM AND ENABLE LOCAL TYPE VII COLLAGEN PRODUCTION IN THE FRONT OF THE EYE.

KRYSTAL BIOTECH ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 CLINICAL TRIAL OF KB803 FOR THE TREATMENT AND PREVENTION OF CORNEAL ABRASIONS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA

PITTSBURGH, MAY 07, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC . (THE COMPANY) (NASDAQ: KRYS) TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE BOFA SECURITIES 2025 HEALTH CARE CONFERENCE ON MAY 14, 2025, IN LAS VEGAS. KRISH S. KRISHNAN, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL TAKE PART IN A FIRESIDE CHAT SCHEDULED AT 11:20 AM PT AND HOST INVESTOR MEETINGS THROUGHOUT THE DAY.

KRYSTAL BIOTECH TO PRESENT AT BOFA SECURITIES 2025 HEALTH CARE CONFERENCE

VYJUVEK APPROVED FOR THE TREATMENT OF DEB FROM BIRTH IN EUROPE APPROVAL ALLOWS FOR DOSING AT HOME OR IN A HEALTHCARE SETTING, AS WELL AS PATIENT OR CAREGIVER ADMINISTRATION IF DEEMED APPROPRIATE BY A HEALTHCARE PROFESSIONAL PITTSBURGH, APRIL 28, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS) ANNOUNCED TODAY THAT ON APRIL 23, 2025, THE EUROPEAN COMMISSION (EC) GRANTED MARKETING AUTHORIZATION TO VYJUVEK (BEREMAGENE GEPERPAVEC-SVDT) FOR THE TREATMENT OF WOUNDS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) WHO HAVE MUTATIONS IN THE COLLAGEN TYPE VII ALPHA 1 CHAIN (COL7A1) GENE, STARTING FROM BIRTH. VYJUVEK IS DESIGNED TO ADDRESS THE GENETIC ROOT CAUSE OF DEB BY DELIVERING FUNCTIONAL COPIES OF THE HUMAN COL7A1 GENE TO PROVIDE WOUND HEALING AND SUSTAINED FUNCTIONAL TYPE VII COLLAGEN PROTEIN EXPRESSION WITH REDOSING.

KRYSTAL BIOTECH ANNOUNCES EUROPEAN COMMISSION APPROVAL OF VYJUVEK FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

PITTSBURGH, APRIL 07, 2025 (GLOBE NEWSWIRE) -- JEUNE AESTHETICS, INC. (JEUNE), A WHOLLY OWNED SUBSIDIARY OF KRYSTAL BIOTECH, INC. (KRYSTAL) (NASDAQ: KRYS) LEVERAGING KRYSTAL'S CLINICALLY VALIDATED GENE-DELIVERY PLATFORM TO FUNDAMENTALLY ADDRESS AND REVERSE THE BIOLOGY OF AGING SKIN, ANNOUNCED TODAY THE APPOINTMENT OF MARC FORTH AS CHIEF EXECUTIVE OFFICER (CEO), EFFECTIVE TODAY. A VETERAN OF THE HEALTHCARE INDUSTRY, MR. FORTH HAS OVER 30 YEARS OF COMMERCIAL AND EXECUTIVE LEADERSHIP EXPERIENCE, WITH AN EXTENSIVE TRACK RECORD OF BUILDING INNOVATIVE COMPANIES AS WELL AS LAUNCHING AND COMMERCIALIZING LEADING BRANDS, INCLUDING BOTOX, ONE OF THE MOST WIDELY RECOGNIZED GLOBAL BRANDS. MR. FORTH HAS ALSO SERVED AS A VALUABLE CONTRIBUTOR ON JEUNE'S BOARD OF DIRECTORS SINCE FEBRUARY 2021.

JEUNE AESTHETICS APPOINTS MARC FORTH AS CHIEF EXECUTIVE OFFICER

PITTSBURGH, FEB. 28, 2025 (GLOBE NEWSWIRE) -- KRYSTAL BIOTECH, INC. (THE COMPANY) (NASDAQ: KRYS), A COMMERCIAL-STAGE BIOTECHNOLOGY COMPANY, TODAY WELCOMED THE EUROPEAN MEDICINES AGENCY'S (EMA'S) ANNOUNCEMENT THAT ITS COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ISSUED A POSITIVE RECOMMENDATION FOR THE EUROPEAN COMMISSION (EC) TO APPROVE VYJUVEK (BEREMAGENE GEPERPAVEC-SVDT, OR B-VEC) FOR THE TREATMENT OF WOUNDS IN PATIENTS WITH DYSTROPHIC EPIDERMOLYSIS BULLOSA (DEB) WHO HAVE MUTATIONS IN THE COLLAGEN TYPE VII ALPHA 1 CHAIN (COL7A1) GENE, STARTING FROM BIRTH. THE CHMP'S POSITIVE OPINION INCLUDES SUPPORT FOR ADMINISTRATION OF VYJUVEK IN EITHER A HEALTH CARE SETTING (E.G.

KRYSTAL BIOTECH RECEIVES POSITIVE CHMP OPINION FOR VYJUVEK FOR THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA

FOURTH QUARTER REVENUES INCREASED 116% TO $91.1 MILLION VERSUS FOURTH QUARTER OF 2023

KRYSTAL BIOTECH ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL AND OPERATING RESULTS

PITTSBURGH, JAN. 14, 2025 (GLOBE NEWSWIRE) -- JEUNE AESTHETICS, INC. (JEUNE), A WHOLLY OWNED SUBSIDIARY OF KRYSTAL BIOTECH, INC. (KRYSTAL) (NASDAQ: KRYS) LEVERAGING KRYSTAL'S CLINICALLY VALIDATED GENE-DELIVERY PLATFORM TO FUNDAMENTALLY ADDRESS AND REVERSE THE BIOLOGY OF AGING SKIN, ANNOUNCED TODAY THE APPOINTMENT OF NISHANT SAXENA AS CHIEF FINANCIAL OFFICER (CFO), EFFECTIVE JANUARY 15, 2025. MR. SAXENA HAS OVER 20 YEARS OF EXPERIENCE IN FINANCE, STRATEGY, CAPITAL MARKETS, MERGERS AND ACQUISITIONS, AND CORPORATE DEVELOPMENT. MOST RECENTLY, HE WAS A MANAGING DIRECTOR IN EVERCORE'S HEALTHCARE GROUP, WHERE HE ADVISED ON TRANSACTIONS TOTALING OVER $500 BILLION IN AGGREGATE VALUE.

Krystal Biotech, Inc.

KRYS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Krystal Biotech, Inc.

KRYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

KRYS